Full Press Release Details
Reports Solid First Quarter 2022 Financial Results
results highlighted by record first quarter revenue of $22.7 million and diluted EPS of $0.34
LAKE CITY, May 12, 2022- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform
for the development of molecular diagnostic tests, announced today financial results for the first quarter ended March 31, 2022.
2022 Financial Results:
are incredibly proud to deliver another solid quarter of growth following our record results in 2021," said Dwight Egan, Co-Diagnostics'
Chief Executive Officer. "We've made substantial progress in the development of our new Co-Dx PCR home diagnostic
testing platform and look forward to submitting for FDA approval later this year.
we are focused on completing development and FDA submission of the new platform," continued Egan. "Our strong balance
sheet and liquidity continue to position us well for additional investments in research and development that will fund our future growth
initiatives. We believe we are at an important point in our growth trajectory that will enable us to expand into new verticals, new markets,
and innovative molecular diagnostic solutions.
we remain very confident about the long-term potential of our business, our ability to accurately forecast Logix Smart COVID-19
Test sales through the balance of the year has diminished due to decreased mask mandates in the United States, continued emergence and
spread of new variants, and persistently low vaccination rates in many parts of the world. As a result, it has become difficult to predict
with any level of precision the cumulative impact of these and other factors on our future financial results. For these reasons, we are
not providing quarterly guidance at this time and will reassess this position in the future," concluded Egan.
Quarter 2022 Business Highlights:
will host a conference call and webcast at 4:30 p.m. EDT today to discuss its financial results with analysts and institutional investors.
The conference call and webcast will be available via:
ir.codiagnostics.com on the Events & Webcasts page
Call: 877-317-6789 (domestic) or 412-317-6789 (international)
call will be recorded and later made available on the Company's website: https://codiagnostics.com.
Co-Diagnostics, Inc.:
Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets new, state-of-the-art diagnostics
technologies. The Company's technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid
molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in
industries other than infectious disease and license the use of those tests to specific customers.
press release contains adjusted EBITDA, which is a non-GAAP measure defined as net income excluding depreciation, amortization, income
tax (benefit) expense, net interest (income) expense, stock-based compensation, and one-time transaction related costs. The Company believes
that adjusted EBITDA provides useful information to management and investors relating to its results of operations. The Company's
management uses this non-GAAP measure to compare the Company's performance to that of prior periods for trend analyses, and for
budgeting and planning purposes. The Company believes that the use of adjusted EBITDA provides an additional tool for investors to use
in evaluating ongoing operating results and trends and in comparing the Company's financial measures with other companies, many
of which present similar non-GAAP financial measures to investors, and that it allows for greater transparency with respect to key metrics
used by management in its financial and operational decision-making.
does not consider the non-GAAP measure in isolation or as an alternative to financial measures determined in accordance with GAAP. The
principal limitation of the non-GAAP financial measure is that it excludes significant expenses that are required by GAAP to be recorded
in the Company's financial statements. In order to compensate for these limitations, management presents the non-GAAP financial
measure together with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but
should not be considered a substitute for, or superior to, GAAP results. A reconciliation tables of the net income, the most comparable
GAAP financial measure to adjusted EBITDA, is included at the end of this release. The Company urges investors to review the reconciliation
and not to rely on any single financial measure to evaluate the company's business.
press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes,"
"expects," "estimates," "intends," "may," "plans," "will" and
similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist
at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include
statements regarding (i) completion of development and FDA submission for approval of the new Co-Dx at-home/point-of-care PCR testing
device, (ii) forecast of strong demand for our broad product portfolio across all end markets, and (iii) our strong balance sheet and
liquidity will continue to position us well for additional investments in research and development that will fund our future growth initiatives.
Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially
from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue
reliance on any forward-looking statements. There can be no assurance that any of the anticipated results will occur on a timely basis
or at all due to certain risks and uncertainties, a discussion of which can be found in our Risk Factors disclosure in our Annual Report
on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 24, 2022, and in our other filings with the SEC. The Company
does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except
as may be required by applicable securities laws.
| Company Contact: | Investor Relations Contact: |
| Andrew Benson | Zachary Mizener |
| Head of Investor Relations | Lambert & Co. |
| +1 801-438-1036 | +1 616-233-0500 |
| investors@codiagnostics.com | zmizener@lambert.com |
INC. AND SUBSIDIARIES
| March 31, 2022 | December 31, 2021 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 97,421,739 | $ | 88,607,234 | ||||
| Marketable investment securities | - | 1,255,266 | ||||||
| Accounts receivable, net | 21,662,403 | 20,839,182 | ||||||
| Inventory | 4,901,057 | 2,004,169 | ||||||
| Prepaid expenses and other current assets | 1,278,598 | 2,338,444 | ||||||
| Note receivable | 75,000 | 75,000 | ||||||
| Total current assets | 125,338,797 | 115,119,295 | ||||||
| Property and equipment, net | 2,252,853 | 1,933,216 | ||||||
| Operating lease right-of-use asset | 604,837 | - | ||||||
| Goodwill | 14,808,411 | 14,706,818 | ||||||
| Intangible assets, net | 27,088,333 | 27,195,000 | ||||||
| Investment in joint venture | 983,614 | 1,004,953 | ||||||
| Note receivable | 75,000 | 75,000 | ||||||
| Total assets | $ | 171,151,845 | $ | 160,034,282 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 1,215,049 | $ | 607,506 | ||||
| Accrued expenses, current | 2,613,218 | 3,859,652 | ||||||
| Operating lease liability, current | 283,299 | - | ||||||
| Contingent consideration liabilities, current | 4,065,537 | 5,767,304 | ||||||
| Income taxes payable | 4,843,592 | 2,213,088 | ||||||
| Deferred revenue | - | 150,000 | ||||||
| Total current liabilities | 13,020,695 | 12,597,550 | ||||||
| Long-term liabilities | ||||||||
| Income taxes payable | 1,284,745 | 1,067,853 | ||||||
| Deferred tax liability | 5,868,728 | 7,228,444 | ||||||
| Operating lease liability | 275,672 | - | ||||||
| Contingent consideration liabilities | 2,987,214 | 4,665,337 | ||||||
| Total long-term liabilities | 10,416,359 | 12,961,634 | ||||||
| Total liabilities | 23,437,054 | 25,559,184 | ||||||
| Stockholders' equity | ||||||||
| Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively | - | - | ||||||
| Common stock, $0.001 par value; 100,000,000 shares authorized; 33,984,068 and 33,819,862 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively | 33,984 | 33,820 | ||||||
| Additional paid-in capital | 81,796,933 | 80,271,999 | ||||||
| Accumulated earnings | 65,883,874 | 54,169,279 | ||||||
| Total stockholders' equity | 147,714,791 | 134,475,098 | ||||||
| Total liabilities and stockholders' equity | $ | 171,151,845 | $ | 160,034,282 |
INC. AND SUBSIDIARIES
STATEMENTS OF OPERATIONS
| Three Months Ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| Revenue | $ | 22,699,044 | $ | 20,024,769 | ||||
| Cost of revenue | 3,281,951 | 3,272,565 | ||||||
| Gross profit | 19,417,093 | 16,752,204 | ||||||
| Operating expenses | ||||||||
| Sales and marketing | 2,652,148 | 1,197,546 | ||||||
| General and administrative | 2,922,195 | 2,935,689 | ||||||
| Research and development | 3,771,327 | 2,217,063 | ||||||
| Depreciation and amortization | 247,264 | 67,005 | ||||||
| Total operating expenses | 9,592,934 | 6,417,303 | ||||||
| Income from operations | 9,824,159 | 10,334,901 | ||||||
| Other income (expense) | ||||||||
| Interest income | 11,393 | 14,657 | ||||||
| Loss on disposition of assets | (93,421 | ) | - | |||||
| Gain on remeasurement of acquisition contingencies | 3,379,890 | - | ||||||
| (Loss) on equity method investment in joint venture | (21,339 | ) | (464,943 | ) | ||||
| Total other income (expense) | 3,276,523 | (450,286 | ) | |||||
| Income before income taxes | 13,100,682 | 9,884,615 | ||||||
| Income tax provision | 1,386,087 | 1,985,640 | ||||||
| Net income | $ | 11,714,595 | $ | 7,898,975 | ||||
| Earnings per common share: | ||||||||
| Basic | $ | 0.35 | $ | 0.28 | ||||
| Diluted | $ | 0.34 | $ | 0.26 | ||||
| Weighted average shares outstanding: | ||||||||
| Basic | 33,935,570 | 28,662,885 | ||||||
| Diluted | 34,711,476 | 30,002,729 |
INC. AND SUBSIDIARIES
AND NON-GAAP MEASURES
of net income to adjusted EBITDA:
| Three Months Ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| Net income | $ | 11,714,595 | $ | 7,898,975 | ||||
| Interest income | (11,393 | ) | (14,657 | ) | ||||
| Depreciation and amortization | 247,264 | 67,005 | ||||||
| Transaction costs (1) | 78,229 | - | ||||||
| Change in fair value of contingent consideration | (3,379,890 | ) | - | |||||
| Stock-based compensation expense | 1,375,097 | 1,513,012 | ||||||
| Income tax provision | 1,386,087 | 1,985,640 | ||||||
| Adjusted EBITDA | $ | 11,409,989 | $ | 11,449,975 |
Expenses incurred relating to the acquisitions of Idaho Molecular and Advanced Conceptions